Cargando…
Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir
Human adenovirus type 19 (HAdV-19) is a major cause of the epidemic keratoconjunctivitis. Outbreaks of keratoconjunctivitis are problematic to human health, especially for infants, the elderly, and immunocompromised individuals. However, the development of anti-HAdV drugs has been hampered by inconv...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218274/ https://www.ncbi.nlm.nih.gov/pubmed/32345035 http://dx.doi.org/10.1177/2040206620921319 |
_version_ | 1783532766029152256 |
---|---|
author | Nakagawara, Kohsuke Hayashi, Hironori Kawaji, Kumi Sasano, Mina Kodama, Eiichi N |
author_facet | Nakagawara, Kohsuke Hayashi, Hironori Kawaji, Kumi Sasano, Mina Kodama, Eiichi N |
author_sort | Nakagawara, Kohsuke |
collection | PubMed |
description | Human adenovirus type 19 (HAdV-19) is a major cause of the epidemic keratoconjunctivitis. Outbreaks of keratoconjunctivitis are problematic to human health, especially for infants, the elderly, and immunocompromised individuals. However, the development of anti-HAdV drugs has been hampered by inconvenient screening systems; therefore, development of a simple screening method is highly desirable. In this study, we identified that HAdV-19 can infect a human lymphoid cell line transformed with human T-cell leukemia virus (MT-2 cells). MT-2 cells supported HAdV-19 replication and showed apparent cytopathic effects within five days post-infection. Using a thiazolyl blue tetrazolium bromide (MTT)-based colorimetric assay on MT-2 cells, we were able to detect the anti-HAdV-19 activities of previously reported nucleoside/tide compounds, including (S)-1–(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (cidofovir), 2′,3′-dideoxycytidine (zalcitabine) and 3′-deoxy-3′-fluorothymidine (trifluridine). Compared with previous methods, this system represents a more simple and rapid method to screen anti-HAdV-19 agents. |
format | Online Article Text |
id | pubmed-7218274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-72182742020-05-18 Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir Nakagawara, Kohsuke Hayashi, Hironori Kawaji, Kumi Sasano, Mina Kodama, Eiichi N Antivir Chem Chemother Short Communication Human adenovirus type 19 (HAdV-19) is a major cause of the epidemic keratoconjunctivitis. Outbreaks of keratoconjunctivitis are problematic to human health, especially for infants, the elderly, and immunocompromised individuals. However, the development of anti-HAdV drugs has been hampered by inconvenient screening systems; therefore, development of a simple screening method is highly desirable. In this study, we identified that HAdV-19 can infect a human lymphoid cell line transformed with human T-cell leukemia virus (MT-2 cells). MT-2 cells supported HAdV-19 replication and showed apparent cytopathic effects within five days post-infection. Using a thiazolyl blue tetrazolium bromide (MTT)-based colorimetric assay on MT-2 cells, we were able to detect the anti-HAdV-19 activities of previously reported nucleoside/tide compounds, including (S)-1–(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (cidofovir), 2′,3′-dideoxycytidine (zalcitabine) and 3′-deoxy-3′-fluorothymidine (trifluridine). Compared with previous methods, this system represents a more simple and rapid method to screen anti-HAdV-19 agents. SAGE Publications 2020-04-28 /pmc/articles/PMC7218274/ /pubmed/32345035 http://dx.doi.org/10.1177/2040206620921319 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/ Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Short Communication Nakagawara, Kohsuke Hayashi, Hironori Kawaji, Kumi Sasano, Mina Kodama, Eiichi N Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir |
title | Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir |
title_full | Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir |
title_fullStr | Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir |
title_full_unstemmed | Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir |
title_short | Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir |
title_sort | application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: zalcitabine has superior activity compared to cidofovir |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218274/ https://www.ncbi.nlm.nih.gov/pubmed/32345035 http://dx.doi.org/10.1177/2040206620921319 |
work_keys_str_mv | AT nakagawarakohsuke applicationofhumanlymphoidcellsfortheevaluationofantiviralsagainsthumanadenovirustype19zalcitabinehassuperioractivitycomparedtocidofovir AT hayashihironori applicationofhumanlymphoidcellsfortheevaluationofantiviralsagainsthumanadenovirustype19zalcitabinehassuperioractivitycomparedtocidofovir AT kawajikumi applicationofhumanlymphoidcellsfortheevaluationofantiviralsagainsthumanadenovirustype19zalcitabinehassuperioractivitycomparedtocidofovir AT sasanomina applicationofhumanlymphoidcellsfortheevaluationofantiviralsagainsthumanadenovirustype19zalcitabinehassuperioractivitycomparedtocidofovir AT kodamaeiichin applicationofhumanlymphoidcellsfortheevaluationofantiviralsagainsthumanadenovirustype19zalcitabinehassuperioractivitycomparedtocidofovir |